The DOI matches its Crossref record; 244 of the 249 references it cites were found in a registry or an index.
Drug repositioning: Progress and challenges in drug discovery for various diseases
Open accessAbstract
Compared with traditional de novo drug discovery, drug repurposing has become an attractive drug discovery strategy due to its low-cost and high efficiency. Through a comprehensive analysis of the candidates that have been identified with drug repositioning potentials, it is found that although some drugs do not show obvious advantages in the original indications, they may exert more obvious effects in other diseases. In addition, some drugs have a synergistic effect to exert better clinical efficacy if used in combination. Particularly, it has been confirmed that drug repositioning has benefits and values on the current public health emergency such as the COVID-19 pandemic, which proved the great potential of drug repositioning. In this review, we systematically reviewed a series of representative drugs that have been repositioned for different diseases and illustrated successful cases in each disease. Especially, the mechanism of action for the representative drugs in new indications were explicitly explored for each disease, we hope this review can provide important insights for follow-up research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Yet, the conventional pathway for novel drug discovery, development, and regulatory approval can span approximately 15 years, rendering it inadequate to address the immediate and growing clinical demands posed by resistant Candida infections [14, 15].”
From Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Completing these stages can take approximately 12–17 years [14].”
From Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies (2025) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Smithburn, K. C. (1952) · The Journal of Immunology · doi:10.4049/jimmunol.69.2.223 · Cited by 3,553
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., Li, X., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.02.008 · Cited by 2,367
Self-citation(2015) · HAL · Cited by 2,238
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“drug substrates remains controversial [14].”
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
Sheahan, T. P., Sims, A. M., Leist, S. R., Schäfer, A., Won, J. J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D. M., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,757
15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
Zhou, Y., Hou, Y., Shen, J., Huang, Y., Martin, W., & Cheng, F. (2020) · Cell Discovery · doi:10.1038/s41421-020-0153-3 · Cited by 1,623
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. M., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrć, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,575
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D. S., Perron, M. J., Bannister, R. M., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,561
Self-citationHung, I. F.-N., Lung, K.-C., Tso, E. Y.-K., Liu, R., Chung, T. W.-H., Chu, M.-Y., Ng, Y.-Y., Lo, J., Chan, J., Tam, A. R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31042-4 · Cited by 1,455
Agostini, M. L., Andres, E. L., Sims, A. M., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,418
Foye's Principles of Medicinal Chemistry
Foye, W. O., Lemke, T., & Williams, D. A. (2012) · Cited by 1,405
Zika Virus Infects Human Cortical Neural Progenitors and Attenuates Their Growth
Tang, H., Hammack, C., Ogden, S. C., Wen, Z., Qian, X., Li, Y., Yao, B., Shin, J., Zhang, F., Lee, E. M., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.02.016 · Cited by 1,292
Baccarani, M. (2006) · Blood · doi:10.1182/blood-2006-02-005686 · Cited by 1,274
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Mitchell, J. D., & Moore, D. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447.pub3 · Cited by 1,123
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · cited 1×
“Many b-amyloid proteins are assembled into insoluble fibers to eventually produce SP [12].”
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
Furuta, Y., Komeno, T., & Nakamura, T. (2017) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.93.027 · Cited by 1,072
Tyagi, S., Gupta, P., Saini, A., Kaushal, C., & Sharma, S. (2011) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/2231-4040.90879 · Cited by 1,017
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P. G., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 915
Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
Corsello, S. M., Nagari, R. T., Spangler, R. D., Rossen, J., Kocak, M., Bryan, J. G., Humeidi, R., Peck, D., Wu, X., Tang, A. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0018-6 · Cited by 878
Self-citationYoshitake, T., Kiyohara, Y., Kato, I., Ohmura, T., Iwamoto, H., Nakayama, K., Ohmori, S., Nomiyama, K., Kawano, H., Ueda, K., et al. (1995) · Neurology · doi:10.1212/wnl.45.6.1161 · Cited by 829 · cited 1×
“Studies have shown that there is a significant relationship between hypertension and Alzheimer's disease [16,17], but the relationship between the two is much complicated.”
Can you teach old drugs new tricks?
Nosengo, N. (2016) · Nature · doi:10.1038/534314a · Cited by 760
Nicotinic acetylcholine involvement in cognitive function in animals
Levin, E. D., & Simon, B. B. (1998) · Psychopharmacology · doi:10.1007/s002130050667 · Cited by 675
Xu, M., Lee, E. M., Wen, Z., Cheng, Y., Huang, W.-K., Qian, X., Julia, T. C. W., Kouznetsova, J., Ogden, S. C., Hammack, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4184 · Cited by 651
Amantadine in the Treatment of Parkinson's Disease
Schwab, R. S. (1969) · JAMA · doi:10.1001/jama.1969.03160070046011 · Cited by 633
Cutaneous melanoma: From pathogenesis to therapy (Review)
Leonardi, G. C., Falzone, L., Salemi, R., Zanghì, A., Spandidos, D. A., McCubrey, J. A., Candido, S., & Libra, M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4287 · Cited by 624
Chen, R. E., & Thorner, J. W. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.05.003 · Cited by 618
Review of Drug Repositioning Approaches and Resources
Xue, H., Li, J., Xie, H., & Wang, Y. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.24612 · Cited by 613
QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
Reilly, J., Ayis, S., Ferrier, I., Jones, S., & Thomas, S. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02035-3 · Cited by 602
Wong, W. W.-L., Dimitroulakos, J., Minden, M., & Penn, L. Z. (2002) · Leukemia · doi:10.1038/sj.leu.2402476 · Cited by 587
Structural basis for human coronavirus attachment to sialic acid receptors
Tortorici, M. A., Walls, A. C., Lang, Y., Wang, C., Li, Z., Koerhuis, D., Boons, G., Bosch, B., Rey, F. A., de Groot, R. J., et al. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0233-y · Cited by 575
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
Rossignol, J. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.07.014 · Cited by 558
Gupta, D., Treon, S. P., Shima, Y., Hideshima, T., Podar, K., Tai, Y.-T., Lin, B. K., Lentzsch, S., Davies, F. E., Chauhan, D., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402295 · Cited by 555
Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy
Ejim, L., Farha, M. A., Falconer, S. B., Wildenhain, J., Coombes, B. K., Tyers, M., Brown, E. D., & Wright, G. D. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.559 · Cited by 525
GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses
Lo, M. K., Jordan, R., Arvey, A. J., Sudhamsu, J., Shrivastava-Ranjan, P., Hotard, A. L., Flint, M., McMullan, L. K., Siegel, D. S., Clarke, M. O., et al. (2017) · Scientific Reports · doi:10.1038/srep43395 · Cited by 514
A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection
Barrows, N. J., Campos, R. K., Powell, S. T., Prasanth, K. R., Schott, G., Soto-Acosta, R., Galarza-Muñoz, G., McGrath, E. L., Urrabaz‐Garza, R., Gao, J., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.07.004 · Cited by 512
Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance
Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038020-00002 · Cited by 508
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502
Mechanisms of action of mycophenolate mofetil
Allison, A. (2005) · Lupus · doi:10.1177/096120330501400102 · Cited by 480
DHODH modulates transcriptional elongation in the neural crest and melanoma
White, R. M., Cech, J. N., Ratanasirintrawoot, S., Lin, C. Y., Rahl, P. B., Burke, C. J., Langdon, E. M., Tomlinson, M. L., Mosher, J. T., Kaufman, C. K., et al. (2011) · Nature · doi:10.1038/nature09882 · Cited by 452
Mechanisms of action of isoniazid
Timmins, G. S., & Deretic, V. P. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05467.x · Cited by 443
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth
Niu, G., Bowman, T., Huang, M., Shivers, S., Reintgen, D., Daud, A., Chang, A., Kraker, A., Jove, R., & Yu, H. (2002) · Oncogene · doi:10.1038/sj.onc.1205859 · Cited by 432
Chen, Y. W., Yiu, C.-P. B., & Wong, K. (2020) · F1000Research · doi:10.12688/f1000research.22457.2 · Cited by 432
Self-citationDeconstructing the Drug Development Process: The New Face of Innovation
Kaitin, K. I. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.293 · Cited by 419
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature reviews. Cancer · doi:10.1038/nrc952 · Cited by 417
Pathogenesis of Alzheimer’s Disease
Rostagno, A. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010107 · Cited by 391
Drug repurposing for antimicrobial discovery
Farha, M. A., & Brown, E. D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0357-1 · Cited by 382
Challenges and opportunities of drug repositioning
Novac, N. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.03.004 · Cited by 381
Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19
Khalili, J. S., Zhu, H. H., Mak, N. S. A., Yan, Y., & Yi, Z. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25798 · Cited by 359
Nucleosides. V. The Monomesylates of 1-(2'-Deoxy-β-D-lyxofuranosyl)thymine1,2
Horwitz, J. P., Chua, J., & Noel, M. (1964) · The Journal of Organic Chemistry · doi:10.1021/jo01030a546 · Cited by 348
Manifestations of Human Cytomegalovirus Infection: Proposed Mechanisms of Acute and Chronic Disease
Britt, W. J. (2008) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-77349-8_23 · Cited by 346
Antifungal Chemical Compounds Identified Using a C. elegans Pathogenicity Assay
Breger, J. A., Fuchs, B. B., Aperis, G., Moy, T. I., Ausubel, F. M., & Mylonakis, E. E. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030018 · Cited by 340
Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential
Xu, J., Shi, P., Li, H., & Zhou, J. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00052 · Cited by 334
Wang, J., Ho, L., Chen, L., Zhao, Z., Zhao, W., Qian, X., Humala, N., Seror, I., Bartholomew, S. R., Rosendorff, C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31547 · Cited by 333
Chen, Y. W., Yiu, C.-P. B., & Wong, K. (2020) · F1000Research · doi:10.12688/f1000research.22457.1 · Cited by 323
Self-citationDrug repositioning for Alzheimer's disease
Corbett, A., Pickett, J., Burns, A. S., Corcoran, J. P. T., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 307
Ge, Y., Tian, T., Huang, S., Wan, F., Li, J., Li, S., Wang, X., Yang, H., Hong, L., Wu, N., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00568-6 · Cited by 300
Hall, D. C., & Ji, H.-F. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101646 · Cited by 298
Zhou, N., Pan, T. S., Zhang, J., Li, Q., Zhang, X., Bai, C., Huang, F., Peng, T., Zhang, J., Liu, C., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.716100 · Cited by 282
Clioquinol: Review of its Mechanisms of Action and Clinical Uses in Neurodegenerative Disorders
Bareggi, S. R., & Cornelli, U. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00231.x · Cited by 251
Batista, A. F., Forny‐Germano, L., Clarke, J. R., Silva, N. M. L. E., Brito‐Moreira, J., Boehnke, S. E., Winterborn, A., Coe, B. C., Lablans, A., Vital, J. F. S., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5056 · Cited by 251
The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication
Sacramento, C. Q., de Melo, G. R., de Freitas, C. S., da Rocha, N. C., Hoelz, L. V. B., Miranda, M. D., Rodrigues, N. F., Marttorelli, A., Ferreira, A. C., Barbosa-Lima, G., et al. (2017) · Scientific Reports · doi:10.1038/srep40920 · Cited by 249
Discovery and development of new antibacterial drugs: learning from experience?
Jackson, N. C., Czaplewski, L. G., & Piddock, L. J. V. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky019 · Cited by 245
Pathogenesis of Alzheimer's disease.
Swerdlow, R. H. (2007) · PubMed · Cited by 242
Mycophenolic Acid Inhibits Dengue Virus Infection by Preventing Replication of Viral RNA
Diamond, M., Zachariah, M. A., & Harris, E. (2002) · Virology · doi:10.1006/viro.2002.1685 · Cited by 237
Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway
Ren, X., Duan, L., He, Q., Zhang, Z., Zhou, Y., Wu, D., Pan, J., Pei, D., & Ding, K. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100146z · Cited by 232
Phenothiazines and Thioxanthenes Inhibit Multidrug Efflux Pump Activity in Staphylococcus aureus
Kaatz, G. W., Moudgal, V. V., Seo, S. M., & Kristiansen, J. E. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.719-726.2003 · Cited by 225
Minocycline affects microglia activation, Aβ deposition, and behavior in APP‐tg mice
Seabrook, T. J., Jiang, L., Maier, M., & Lemere, C. A. (2006) · Glia · doi:10.1002/glia.20338 · Cited by 223
Sofosbuvir: A novel treatment option for chronic hepatitis C infection
Bhatia, H. K., Singh, H., Grewal, N., & Natt, N. K. (2014) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.142464 · Cited by 223
Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases
Berger, N. A., Besson, V. C., Boulares, A. H., Bürkle, A., Chiarugi, A., Clark, R. S. B., Curtin, N. J., Cuzzocrea, S., Dawson, T. M., Dawson, V. L., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13748 · Cited by 219
Amantadine in the treatment of Parkinson's disease and other movement disorders
Rascol, O., Fabbri, M., & Poewe, W. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00249-0 · Cited by 216
Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and ResistancePreprint
Zeng, D., Debabov, D. V., Hartsell, T. L., Cano, R. J., Adams, S. M., Schuyler, J. A., McMillan, R. K., & Pace, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026989 · Cited by 212
Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2
Valencia, D. N. (2020) · Cureus · doi:10.7759/cureus.7386 · Cited by 206
Alem, M. A. S., & Douglas, L. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.41-47.2004 · Cited by 205
Zhai, B., Wu, C., Wang, L., Sachs, M. S., & Lin, X. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00212-12 · Cited by 205
Tobita, T., Takeshita, A., Kitamura, K., Ohnishi, K., Yanagi, M., Hiraoka, A., Karasuno, T., Takeuchi, M., MIYAWAKI, S., Ueda, R., et al. (1997) · Blood · doi:10.1182/blood.v90.3.967 · Cited by 198
The value of drug repositioning in the current pharmaceutical market
Tobinick, E. L. (2009) · Drug News & Perspectives · doi:10.1358/dnp.2009.22.2.1303818 · Cited by 194
PPAR dual agonists: Are they opening Pandora's Box?
Balakumar, P., ROSE, M., Ganti, S. S., Krishan, P., & Singh, M. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.03.002 · Cited by 192
Metabotropic Glutamate Receptor 1 and Glutamate Signaling in Human Melanoma
Namkoong, J., Shin, S., Lee, H. J., Marín, Y. E., Wall, B., Goydos, J. S., & Chen, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3665 · Cited by 191
Nowak-Sliwinska, P. M., Scapozza, L., & Altaba, A. R. I. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.005 · Cited by 188
Zhang, X., Song, Y., Ci, X., An, N., Ju, Y., Li, H., Wang, X., Han, C., Cui, J., & Deng, X. (2008) · Inflammation Research · doi:10.1007/s00011-008-8007-8 · Cited by 187
Warburg, O. H. (1956) · PubMed · Cited by 187
Antifungal Drug Discovery: Something Old and Something New
Butts, A., & Krysan, D. J. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002870 · Cited by 182
Nucleoside Analogues as Antibacterial Agents
Thomson, J. M., & Lamont, I. L. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00952 · Cited by 177
Sassano, A., & Platanias, L. C. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.11.036 · Cited by 171
Li, C., Zhu, X., Ji, X., Quanquin, N. M., Deng, Y.-Q., Tian, M., Aliyari, R., Zuo, X., Yuan, L., Afridi, S. K., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.09.034 · Cited by 171
Ge, Y., Tian, T., Huang, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.11.986836 · Cited by 168
Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review
Mohamed, K., Yazdanpanah, N., Saghazadeh, A., & Rezaei, N. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104490 · Cited by 167
Repurposing Strategies for Therapeutics
Sleigh, S. H., & Barton, C. L. (2010) · Pharmaceutical Medicine · doi:10.1007/bf03256811 · Cited by 166
Biscaro, B., Lindvall, O., Tesco, G., Ekdahl, C. T., & Nitsch, R. M. (2012) · Neurodegenerative Diseases · doi:10.1159/000330363 · Cited by 164
Martirosyan, A., Clendening, J. W., Goard, C. A., & Penn, L. Z. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-103 · Cited by 160
Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer
Naccarati, A., Vymetalkova, V. P., Pardini, B., Vodičková, Ľ., Hemminki, K., Kumar, R., & Vodička, P. (2012) · Mutagenesis · doi:10.1093/mutage/ger067 · Cited by 145
Safety of chloroquine in chemosuppression of malaria during pregnancy.
Wolfe, M. S., & Cordero, J. F. (1985) · BMJ · doi:10.1136/bmj.290.6480.1466 · Cited by 145
Disulfiram induces apoptosis in human melanoma cells: a redox-related process.
Cen, D., Gonzalez, R. I., Buckmeier, J. A., Kahlon, R. S., Tohidian, N. B., & Meyskens, F. L. (2002) · PubMed · Cited by 145
Ley, J. P., Krammer, G. E., Reinders, G., Gatfield, I. L., & Bertram, H. (2005) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf0505170 · Cited by 140
Ivermectin, a potential anticancer drug derived from an antiparasitic drug
Tang, M., Hu, X., Wang, Y., Yao, X., Zhang, W., Yu, C., Cheng, F., Li, J., & Fang, Q. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105207 · Cited by 139
Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin
Endres, K., Fahrenholz, F., Lotz, J., Hiemke, C., Teipel, S. J., Lieb, K., Tüscher, O., & Fellgiebel, A. (2014) · Neurology · doi:10.1212/wnl.0000000000001017 · Cited by 138
Lin, S.-Y., Liu, C., Chang, Y., Zhao, J., Perlman, S. M., & Hou, M. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500089r · Cited by 137
Kornblau, S. M., Banker, D. E., Stirewalt, D. L., Shen, D. D., Lemker, E., Verstovšek, S., Estrov, Z. E., Faderl, S. H., Cortes, J. E., Beran, M., et al. (2006) · Blood · doi:10.1182/blood-2006-08-044446 · Cited by 136
Drug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136
Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitroPreprint
Yamamoto, N., Matsuyama, S., Hoshino, T., & Yamamoto, N. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.06.026476 · Cited by 136
Kashour, Z., Riaz, M. A., Garbati, M. A., AlDosary, O., Tlayjeh, H., Gerberi, D., Murad, M. H., Sohail, M. R., Kashour, T. S., & Tleyjeh, I. M. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa403 · Cited by 135
A depot neuroleptic withdrawal study
Wistedt, B., J�rgensen, A., & Wiles, D. (1982) · Psychopharmacology · doi:10.1007/bf00433729 · Cited by 134
Smith, M. D., & Smith, J. C. (2020) · ChemRxiv · doi:10.26434/chemrxiv.11871402 · Cited by 130
Slow-Cycling Therapy-Resistant Cancer Cells
Moore, N., Houghton, J., & Lyle, S. R. (2011) · Stem Cells and Development · doi:10.1089/scd.2011.0477 · Cited by 128
Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques
Guedj, J., Piorkowski, G., Jacquot, F., Madelain, V., Nguyen, T. H. T., Rodallec, A., Günther, S., Carbonnelle, C., Mentré, F., Raoul, H., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002535 · Cited by 128
Pharmacological treatment of cardiac glycoside poisoning
Roberts, D. M., Galappatthy, G., Dunuwille, A., & Chan, B. S. H. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12814 · Cited by 126
Nyce, J. W., MAGEE, P. N., Hard, G. C., & Schwartz, A. G. (1984) · Carcinogenesis · doi:10.1093/carcin/5.1.57 · Cited by 125
Malignant Tumors of the Female Reproductive System
Weiderpass, E., & Labrèche, F. (2012) · Safety and Health at Work · doi:10.5491/shaw.2012.3.3.166 · Cited by 122
Chen, H., Yang, Z., Ding, C., Chu, L., Zhang, Y., Terry, K., Liu, H., Shen, Q., & Zhou, J. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3003082 · Cited by 121
Self-citationPPAR influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis
Nicol, C. J. B. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh160 · Cited by 120
Amantadine Enhancement of Arousal and Cognition After Traumatic Brain Injury
Sawyer, E., Maura, L. S., & Ohlinger, M. J. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k284 · Cited by 120
Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19
Talluri, S. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323666200814132149 · Cited by 119
Tande, A. J., Osmon, D. R., Greenwood‐Quaintance, K. E., Mabry, T. M., Hanssen, A. D., & Patel, R. (2014) · mBio · doi:10.1128/mbio.01910-14 · Cited by 117
Paris, D., Bachmeier, C., Patel, N., Quadros, A., Volmar, C.-H., Laporte, V., Ganey, J., Beaulieu-Abdelahad, D., Ait-Ghezala, G., Crawford, F., et al. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00180 · Cited by 114
A depot neuroleptic withdrawal study
Wistedt, B. (1981) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1981.tb00761.x · Cited by 113
c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice
Cancino, G. I., Perez de Arce, K., Castro, P. U., Toledo, E. M., von Bernhardi, R., & Alvarez, A. R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.007 · Cited by 110
Kodama, M., Kodama, T., Newberg, J. Y., Katayama, H., Kobayashi, M., Hanash, S., Yoshihara, K., Wei, Z., Tien, J. C.-Y., Rangel, R., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705441114 · Cited by 108
Suramin inhibits chikungunya virus replication through multiple mechanisms
Albulescu, I. C., van Hoolwerff, M., Wolters, L. A., Bottaro, E., Nastruzzi, C., Yang, S. C., Tsay, S., Hwu, J. R., Snijder, E. J., & van Hemert, M. J. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.06.013 · Cited by 106
Morrison, B. W., Doudican, N. A., Patel, K. R., & Orlow, S. J. (2010) · Melanoma Research · doi:10.1097/cmr.0b013e328334131d · Cited by 106
Is the Amyloid Hypothesis of Alzheimer's disease therapeutically relevant?
Teich, A. F., & Arancio, O. (2012) · Biochemical Journal · doi:10.1042/bj20120653 · Cited by 105
Human Cytomegalovirus 86-Kilodalton IE2 Protein Blocks Cell Cycle Progression in G 1
Wiebusch, L., & Hagemeier, C. (1999) · Journal of Virology · doi:10.1128/jvi.73.11.9274-9283.1999 · Cited by 104
Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock
Mothay, D., & Ramesh, K. V. (2020) · VirusDisease · doi:10.1007/s13337-020-00585-z · Cited by 104
Über die Entstehung der Krebszellen
Warburg, O. H. (2009) · Oncologia · doi:10.1159/000223920 · Cited by 102
Synergistic drug combination effectively blocks Ebola virus infection
Sun, W., He, S., Martínez‐Romero, C., Kouznetsova, J., Tawa, G. J., Xu, M., Shinn, P., Fisher, E. G., Long, Y., Motabar, O., et al. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.11.017 · Cited by 99
Reddy, D., Kumavath, R., Barh, D., Azevedo, V., & Ghosh, P. (2020) · Molecules · doi:10.3390/molecules25163596 · Cited by 99
Repurposing Non-Antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections
Younis, W., Thangamani, S., & Seleem, M. N. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150506154434 · Cited by 99
McLean, J. E., Neidhardt, E. A., Grossman, T. H., & Hedstrom, L. (2001) · Biochemistry · doi:10.1021/bi001810q · Cited by 97
Wiciński, M., Socha, M. W., Malinowski, B., Wódkiewicz, E., Walczak, M., Górski, K. M., Słupski, M., & Pawlak-Osińska, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051050 · Cited by 94
Kumar, S., Bryant, C. S., Chamala, S., Qazi, A. M., Seward, S. M., Pal, J., Steffes, C. P., Weaver, D. W., Morris, R. T., Malone, J. M., et al. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-26 · Cited by 92
Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virus
Balasubramanian, A., TERAMOTO, T., Kulkarni, A. A., Bhattacharjee, A. K., & Padmanabhan, R. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.11.015 · Cited by 90
Zhang, Y., Li, Z., Chu, W., Wang, B., Zhang, J., Zhao, M., Li, X., Li, B., Lu, Y., Yang, B., et al. (2010) · Cellular Physiology and Biochemistry · doi:10.1159/000324012 · Cited by 89
Self-citationThe Fundamental Role of the p53 Pathway in Tumor Metabolism and Its Implication in Tumor Therapy
Shen, L., Sun, X. Y., Fu, Z., Yang, G., Li, J., & Yao, L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3040 · Cited by 89
Antoniani, D., Rossi, E., Rinaldo, S., Bocci, P., Lolicato, M., Paiardini, A., Raffaelli, N., Cutruzzolà, F., & Landini, P. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-4875-0 · Cited by 87
Yokoyama, Y., Xin, B., Shigeto, T., Umemoto, M., Kasai-Sakamoto, A., Futagami, M., Tsuchida, S., Al‐Mulla, F., & Mizunuma, H. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0722 · Cited by 86
Antimicrobial Activity of Topical Skin Pharmaceuticals – An In vitro Study
Alsterholm, M., Karami, N., & Faergemann, J. (2010) · Acta Dermato Venereologica · doi:10.2340/00015555-0840 · Cited by 85
Ploß, A., & Dubuisson, J. (2012) · Gut · doi:10.1136/gutjnl-2012-302048 · Cited by 85
Chuang, H., Chang, Y.-F., & Hwang, J. (2011) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2011.02.016 · Cited by 83
Sweeney, J. E., Bachman, E. S., & Coyle, J. T. (1990) · Psychopharmacology · doi:10.1007/bf02245921 · Cited by 79
Bexarotene: A promising anticancer agent
Qu, L., & Tang, X. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1140-4 · Cited by 78
Cholinesterase inhibition by galanthamine and lycoramine
Irwin, R. L., & Smith, H. J. (1960) · Biochemical Pharmacology · doi:10.1016/0006-2952(60)90030-7 · Cited by 78
Zeng, X., Liu, L., Zheng, M., Sun, H., Xiao, J., Lu, T., Huang, G., Chen, P., Zhang, J., Zhu, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7984 · Cited by 77
Self-citationThioridazine: resurrection as an antimicrobial agent?
Thanacoody, R. H. K. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.03021.x · Cited by 76
Ayerbe-Algaba, R., Gil-Marqués, M. L., Me, J.-M., Sánchez-Encinales, V., Parra-Millán, R., Pachón-Ibáñez, M. E., Pachón, J., & Smani, Y. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00348 · Cited by 76
Chen, M., Yang, W.-L. R., Lin, K., Liu, C.-H., Liu, Y.-W., Huang, K., Chang, P. M., Lai, J.-M., Hsu, C.-N., Chao, K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027186 · Cited by 75
Sedlacek, M., Gemery, J. M., Cheung, A. L., Bayer, A. S., & Remillard, B. D. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.014 · Cited by 75
Dewan, M. Z. (2006) · Blood · doi:10.1182/blood-2005-02-0735 · Cited by 75
Schmidmaier, R., Baumann, P., Bumeder, I., Meinhardt, G., Straka, C., & Emmerich, B. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.00902.x · Cited by 71
Fighting viruses with antibiotics: an overlooked path
Colson, P., & Raoult, D. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.07.004 · Cited by 71
The Case of Galantamine: Repurposing and Late Blooming of a Cholinergic Drug
Mucke, H. A. (2015) · Future Science OA · doi:10.4155/fso.15.73 · Cited by 68
Amantadine as receptor antagonist: new possibilities for therapeutic applications?
Stoof, J. C., Booij, J., & Drukarch, B. (1992) · Clinical Neurology and Neurosurgery · doi:10.1016/0303-8467(92)90006-o · Cited by 67
Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus
Mukhopadhyay, R., Roy, S., Venkatadri, R., Su, Y., Ye, W., Barnaeva, E. S., Griner, L. A. M., Southall, N. T., Hu, X., Wang, A. Q., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005717 · Cited by 66
New insights into the mechanism of antifungal action of 8-hydroxyquinolines
Pippi, B., Lopes, W., Reginatto, P., Silva, F. É. K., Joaquim, A. R., Alves, R. J., Silveira, G. P., Vainstein, M. H., de Andrade, S. F., & Fuentefría, A. M. (2018) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2018.07.017 · Cited by 66
Indu, P., Rameshkumar, M. R., Arunagirinathan, N., Al-Dhabi, N. A., Arasu, M. V., & Savarimuthu Ignacimuthu, S. J. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.10.015 · Cited by 66
Forette, F., Seux, M., & Staessen, J. A. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)01017-6 · Cited by 65
Kobayashi, Y., Kashima, H., Wu, R., Jung, J.-G., Kuan, J.-C., Gu, J., Xuan, J., Sokoll, L. J., Visvanathan, K., Shih, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3368 · Cited by 64
Bachmeier, C. J., Beaulieu‐Abdelahad, D., MULLAN, M. J., & Paris, D. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.03.048 · Cited by 64
Itraconazole targets cell cycle heterogeneity in colorectal cancer
Buczacki, S. J. A., Popova, S. A., Biggs, E. K., Koukorava, C., Buzzelli, J. N., Vermeulen, L., Hazelwood, L. D., Francies, H. E., Garnett, M. J., & Winton, D. J. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171385 · Cited by 64
Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1
Lee, W., Lee, W.-T., Cheng, C., Chen, K., Chou, C., Chung, C., Sun, M.-S., Cheng, H., Ho, M.-N., & Lin, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4768 · Cited by 58
Ikezoe, T., Daar, E. S., Hisatake, J., Taguchi, H., & Koeffler, H. P. (2000) · Blood · doi:10.1182/blood.v96.10.3553 · Cited by 57
Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer
Kobayashi, Y., Kashima, H., Rahmanto, Y. S., Banno, K., Yu, Y., Matoba, Y., Watanabe, K., Iijima, M., Takeda, T., Kunitomi, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20046 · Cited by 57
Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis
Truong, M., Monahan, L. G., Carter, D. A., & Charles, I. G. (2018) · PeerJ · doi:10.7717/peerj.4761 · Cited by 57
Costa Silva, R. A., da Silva, C. R., de Andrade Neto, J. B., da Silva, A. R., Campos, R. S., Sampaio, L. S., do Nascimento, F. B. S. A., da Silva Gaspar, B., da Cruz Fonseca, S. G., Josino, M. A. A., et al. (2017) · Microbial Pathogenesis · doi:10.1016/j.micpath.2017.04.008 · Cited by 56
Brent, T. P., & Remack, J. S. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.14.6779 · Cited by 56
Human Cytomegalovirus Inhibition by Cardiac Glycosides: Evidence for Involvement of the hERG Gene
Kapoor, A., Cai, H., Forman, M., He, R., Shamay, M., & Arav‐Boger, R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00898-12 · Cited by 56
Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology
Guo, J., Cheng, J., North, B. J., & Wei, W. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.07.001 · Cited by 55
In Vitro Interactions between Antifungals and Immunosuppressive Drugs against Zygomycetes
Dannaoui, É., Schwarz, P., & Lortholary, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00184-09 · Cited by 54
Mehnert, J. M., Silk, A. W., Lee, J. H., Dudek, L., Jeong, B., Li, J., Schenkel, J. M., Sadimin, E. T., Kane, M., Lin, H., et al. (2018) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12694 · Cited by 54
Hayes, C. D., Dey, D., Palavicini, J. P., Wang, H., Patkar, K. A., Minond, D., Nefzi, A., & Lakshmana, M. K. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-81 · Cited by 52
Hsieh, S., Wu, Y.-C., Zou, G., Nerurkar, V. R., Shi, P., & Wang, W. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.610428 · Cited by 51
Alendronate Inhibits Intraperitoneal Dissemination in In vivo Ovarian Cancer Model
Hashimoto, K., Morishige, K.-I., Sawada, K., Tahara, M., Kawagishi, R., Ikebuchi, Y., Sakata, M., Tasaka, K., & Murata, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.540.65.2 · Cited by 49
Reprofiled anthelmintics abate hypervirulent stationary-phase Clostridium difficile
Gooyit, M., & Janda, K. D. (2016) · Scientific Reports · doi:10.1038/srep33642 · Cited by 48
Yang, W., Hu, X., Han, H., Shi, L., Feng, G.-F., Liu, Y., & Qian, Y. (2014) · Neurological Research · doi:10.1179/1743132813y.0000000295 · Cited by 47
Drug repurposing in neurological diseases: an integrated approach to reduce trial and error
Clout, A. E., Pasqua, O. E. D., Hanna, M. G., Orlu, M., & Pitceathly, R. D. S. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-320879 · Cited by 47
Amlodipine: a cardiovascular drug with powerful antimicrobial property.
Kumar, K. A., Ganguly, K., Mazumdar, K., Dutta, N. K., Dastidar, S. G., & Chakrabarty, A. N. (2003) · PubMed · Cited by 46
Jieensinue, S., Zhu, H., Li, G., Dong, K., Liang, M., & Li, Y. (2018) · BMC Cell Biology · doi:10.1186/s12860-018-0174-z · Cited by 46
A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor
Ami, E. A. B., & Demetri, G. D. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1152258 · Cited by 45
Clioquinol, an alternative antimicrobial agent against common pathogenic microbe
You, Z., Ran, X., Dai, Y., & Ran, Y. (2018) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2018.03.007 · Cited by 45
Mazumdar, K., Kumar, K. A., & Dutta, N. K. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.05.003 · Cited by 44
Targeting Parkinson’s - Tyrosine Hydroxylase and Oxidative Stress as Points of Interventions
Khan, M. S., Tabrez, S. S. M., Priyadarshini, M., Priyamvada, S., & Khan, M. M. (2012) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152712800792848 · Cited by 43
Trombetta, R. P., Dunman, P. M., Schwarz, E. M., Kates, S. L., & Awad, H. A. (2018) · mSphere · doi:10.1128/msphere.00422-18 · Cited by 43
Basu, L. R., Mazumdar, K., Dutta, N. K., Karak, P., & Dastidar, S. G. (2005) · Microbiological Research · doi:10.1016/j.micres.2004.10.002 · Cited by 42
Sato, A., Saito, Y., Sugiyama, K., Sakasegawa, N., Muramatsu, T., Fukuda, S., Yoneya, M., Kimura, M., Ebinuma, H., Hibi∥, T., et al. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24541 · Cited by 41
Zhu, Y., Zuo, W., Chen, L., Bian, S., Jing, J., Gan, C., Wu, X., Liu, H., Su, X., Hu, W., et al. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.08.012 · Cited by 41
Self-citationCristofori, P. G., Lanzoni, A., Quartaroli, M., Pastorino, A. M., Zancanaro, C., Cominacini, L., Gaviraghi, G., & Turton, J. A. (2000) · Journal of Hypertension · doi:10.1097/00004872-200018100-00010 · Cited by 40
Sharma, V. D., Lyons, K., & Pahwa, R. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s144481 · Cited by 40
Galantamine: Additional Benefits to Patients with Alzheimer’s Disease
Lilienfeld, S., & Parys, W. (2000) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051228 · Cited by 39
Research works printed but not linked: 12
- Shahnawaz Khan, 2012, 11, 369
- Rascol, 2021, 20, 1048
- Naccarati, 2012, 2, 211
- Chen, 2011, 6, 27186
- Schmidmaier, 2007, 79, 240
- Leonardi, 2018, 52, 1071
- Niu, 2002, 21, 7001
- Riedel, 2017, Drug repurposing approach identifies a synergistic drug combination of an antifungal agent and an experimental organometallic drug for melanoma treatment, Mol. Pharm., 116
- You, 2018, 28, 492
- Alsterholm, 2010, 90, 239
- Pippi, 2019, 27, 41
- Barrows, 2016, A screen of FDA-approved drugs for inhibitors of Zika virus infection, Cell Host Microbe, 259, 10.1016/j.chom.2016.07.004 · DOI
Cited by
Sorted by citations
Bai, R., Li, Y., Jian, L., Yue-hui, Y., Zhao, L., & Wei, M. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01645-2 · Cited by 296
Adachi, T., El-Hattab, A. W., Jain, R., Nogales Crespo, K. A., Quirland Lazo, C. I., Scarpa, M., Summar, M., & Wattanasirichaigoon, D. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064732 · Cited by 168
KG-Predict: A knowledge graph computational framework for drug repurposing
Gao, Z., Ding, P., & Xu, R. (2022) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2022.104133 · Cited by 103
Triclosan: A Small Molecule with Controversial Roles
Sinicropi, M. S., Iacopetta, D., Ceramella, J., Catalano, A. A., Mariconda, A., PELLEGRINO, M. A., Saturnino, C., Longo, P., & Aquaro, S. (2022) · Antibiotics · doi:10.3390/antibiotics11060735 · Cited by 96
A comprehensive review of computational cell cycle models in guiding cancer treatment strategies
Ma, C., & Gürkan-Çavusoglu, E. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00397-7 · Cited by 63
Metadata
- Authors
- Hua, Y., Dai, X., Xu, Y., Xing, G., Liu, H., Lu, T., Chen, Y., & Zhang, Y.
- Affiliations
- China Pharmaceutical University (CN)
- Corresponding author
- Chen, Yadong
- Zhang, Yanmin
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2022-04
- Volume
- 234
- Pages
- 114239
- ISSN
- 0223-5234 (ISSN-L)
- PMC
- PMC8883737
- OpenAlex
- W4220885170
- Cited by
- 232
- References
- 249
- Citations by year
- 2026: 35 · 2025: 77 · 2024: 80 · 2023: 31 · 2022: 9
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- European Journal of Medicinal Chemistry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- drug repurposing, drug discovery, drug synergy, combination therapy, COVID-19 pandemic, mechanism of action
- MeSH terms
- COVID-19 Drug Treatment, Humans, Drug Discovery, Drug Repositioning, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
